收费全文 | 6592篇 |
免费 | 358篇 |
国内免费 | 16篇 |
医药卫生 | 6966篇 |
2023年 | 64篇 |
2022年 | 77篇 |
2021年 | 323篇 |
2020年 | 194篇 |
2019年 | 251篇 |
2018年 | 275篇 |
2017年 | 190篇 |
2016年 | 233篇 |
2015年 | 267篇 |
2014年 | 346篇 |
2013年 | 378篇 |
2012年 | 565篇 |
2011年 | 509篇 |
2010年 | 276篇 |
2009年 | 212篇 |
2008年 | 372篇 |
2007年 | 304篇 |
2006年 | 300篇 |
2005年 | 231篇 |
2004年 | 219篇 |
2003年 | 182篇 |
2002年 | 136篇 |
2001年 | 112篇 |
2000年 | 109篇 |
1999年 | 98篇 |
1998年 | 46篇 |
1997年 | 31篇 |
1996年 | 21篇 |
1995年 | 20篇 |
1994年 | 18篇 |
1993年 | 30篇 |
1992年 | 59篇 |
1991年 | 37篇 |
1990年 | 34篇 |
1989年 | 60篇 |
1988年 | 45篇 |
1987年 | 22篇 |
1986年 | 30篇 |
1985年 | 29篇 |
1984年 | 24篇 |
1983年 | 37篇 |
1981年 | 13篇 |
1980年 | 18篇 |
1979年 | 23篇 |
1978年 | 13篇 |
1975年 | 11篇 |
1973年 | 18篇 |
1972年 | 13篇 |
1971年 | 12篇 |
1970年 | 13篇 |
Purpose
A hydrogel rectal spacer (HRS) is a medical device that is approved by the U.S. Food and Drug Administration to increase the separation between the prostate and rectum. We conducted a cost-effectiveness analysis of HRS use for reduction in radiation therapy (RT) toxicities in patients with prostate cancer (PC) undergoing external beam RT (EBRT).Methods and Materials
A multistate Markov model was constructed from the U.S. payer perspective to examine the cost-effectiveness of HRS in men with localized PC receiving EBRT (EBRT alone vs EBRT + HRS). The subgroups analyzed included site of HRS placement (hospital outpatient, physician office, ambulatory surgery center) and proportion of patients with good baseline erectile function (EF). Data on EF, gastrointestinal and genitourinary toxicities incidence, and potential risks associated with HRS implantation were obtained from a recently published randomized clinical trial. Health utilities and costs were derived from the literature and the 2018 Physician Fee Schedule and were discounted 3% annually. Quality-adjusted life years (QALYs) and costs were modeled for a 5-year period from receipt of RT. Probabilistic sensitivity analysis and value-based threshold analyses were conducted.Results
The per-patient 5-year incremental cost for spacers administered in a hospital outpatient setting was $3578, and the incremental effectiveness was 0.0371 QALYs. The incremental cost-effectiveness ratio was $96,440/QALY for patients with PC undergoing HRS insertion in a hospital and $39,286/QALY for patients undergoing HRS insertion in an ambulatory facility. For men with good baseline EF, the incremental cost-effectiveness ratio was $35,548/QALY and $9627/QALY in hospital outpatient and ambulatory facility settings, respectively.Conclusions
Based on the current Medicare Physician Fee Schedule, HRS is cost-effective at a willingness to pay threshold of $100,000. These results contain substantial uncertainty, suggesting more evidence is needed to refine future decision-making. 相似文献Methods: A systematic literature search was performed to identify relevant randomized controlled trials (RCTs). Key outcomes of interest were clinical response (CD activity index [CDAI] reduction of 100 points; CDAI-100) and remission (CDAI score under 150 points; CDAI < 150). A treatment sequence Bayesian NMA was conducted to account for the re-randomization of patients based on different clinical definitions, the lack of similarity of the common comparator for each trial and the full treatment pathway from the induction phase onwards.
Results: Thirteen RCTs were identified. Ustekinumab 90?mg q8w was associated with statistically significant improvement in clinical response relative to placebo and vedolizumab 300?mg. For clinical remission, ustekinumab 90?mg q8w was associated with statistically significant improvement relative to placebo and vedolizumab 300?mg q8w. Findings from sub-population analyses had similar results but were not statistically significant.
Conclusions: The NMA suggest that ustekinumab is associated with the highest likelihood of reaching response or remission at 1?year compared with placebo, adalimumab and vedolizumab. Results should be interpreted with caution because this is a novel methodology; however, the treatment sequence analysis may be the most methodologically sound analysis to derive estimates of comparative efficacy in CD in the absence of head-to-head evidence. 相似文献